Objectives: Opiorphin is a recently discovered peptide shown to inhibit the enkephalin-degrading enzymes and prolong the effects of enkephalins. Although opiorphin is found in high concentrations in saliva, the relationship between salivary opiorphin and orofacial pains is not yet fully understood. We aimed to determine salivary opiorphin concentrations in dental pain related to symptomatic irreversible pulpitis (SIP), and symptomatic apical periodontitis (SAP).
Design: 39 patients participated in this study. The participants were categorized into SIP and SAP based on their diagnosis. All the patients were treated with root canal treatment. Saliva specimens were collected, and pain levels were recorded at pre-treatment, 7 days post-treatment and 30 days post-treatment. Saliva opiorphin levels were measured using a commercially available ELISA kit. Pre-treatment and post-treatment opiorphin levels were evaluated using repeated measures ANOVA. Correlations between VAS scores, opiorphin levels and age were evaluated using Spearman's Rank Correlation.
Results: The average saliva opiorphin level pre-treatment, 7 days post-treatment and 30 days post-treatment were 31.28 ± 7.10 ng/ml, 20.41 ± 2.67 ng/ml and 18.61 ± 2.05 ng/ml respectively. Significantly higher pre-treatment opiorphin levels were observed in the SIP group compared to the SAP group. A strong correlation was observed between the pre-treatment pain levels and the saliva opiorphin concentrations.
Conclusions: Our findings indicate that saliva opiorphin levels increase in inflammation related dental pain. The level of salivary opiorphin is strongly correlated with the reported level of pain. The extent of the inflammation (pulpal vs. periodontal) also affects the opiorphin level.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.archoralbio.2018.12.006 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparison of Salivary Opiorphin in Burning Mouth Syndrome and Healthy Subjects and Its Correlation With Psychiatric Disorders.
Clin Exp Dent Res
December 2024
Department of Oral and Maxillofacial Medicine, School of Dentistry, Tehran University of Medical Sciences, Tehran, Iran.
Objectives: Burning mouth syndrome (BMS) is a chronic disease in which the patient experiences a burning sensation in the oral mucosa without any pathological cause. Opiorphin is a pentapeptide that prevents pain and can have an antidepressant effect. The aim of this study was to evaluate salivary opiorphin concentration in BMS and healthy subjects.
View Article and Find Full Text PDFOpiorphin: an endogenous human peptide with intriguing application in diverse range of pathologies.
Inflammopharmacology
October 2024
Chikara College of Pharmacy, Chitkara University, Rajpura, Punjab, 140401, India.
Article Synopsis
- Mammalian zinc ectopeptidases help turn off nerve and hormone signals on cells.
- A substance called Opiorphin stops these ectopeptidases, making it easier for the body to manage pain and possibly improve mood.
- Opiorphin could be useful for treating various health problems, including pain, mood disorders, and neurodegeneration.
Effects of the Dual FAAH/MAGL Inhibitor AKU-005 on Trigeminal Hyperalgesia in Male Rats.
Cells
May 2024
Section of Translational Neurovascular Research, IRCCS Mondino Foundation, Via Mondino 2, 27100 Pavia, Italy.
Article Synopsis
- The study investigates the effects of the dual FAAH/MAGL inhibitor AKU-005 on migraine pain in a rat model induced by nitroglycerin (NTG).
- Administration of AKU-005 reduced pain sensitivity and levels of calcitonin gene-related peptide (CGRP) and pro-inflammatory markers in brain areas but not in serum endocannabinoid levels.
- The findings suggest that AKU-005 may help relieve migraine pain by lowering CGRP production and related inflammation, independent of its effects on the endocannabinoid system.
Time-course of pain and salivary opiorphin release in response to oral capsaicin differ in burning mouth syndrome patients, temporomandibular disorders patients and control subjects.
Clin Oral Investig
April 2024
Laboratoire de Neurobiologie Orofaciale, UFR Odontologie, Université Paris Cité, Paris, 75006, France.
Article Synopsis
- The study aimed to investigate the release of opiorphin, an analgesic peptide, after stimulating the tongue with capsaicin, focusing on three groups: healthy individuals, those with Burning Mouth Syndrome (BMS), and individuals with painful Temporomandibular disorders (TMDp).* -
- Results showed that opiorphin levels were significantly higher in the TMDp group compared to healthy controls and that the BMS group showed increased levels after stimulation, indicating different pain response mechanisms among the groups.* -
- The findings suggest that understanding the regulation of opiorphin in orofacial pain conditions may offer clinical insights and the potential for further research in pain management.*
Salivary opiorphin levels in denture-related traumatic ulcers.
Oral Dis
July 2024
Department of Basic Sciences, Faculty of Dentistry, Ankara Yıldırım Beyazıt University, Ankara, Turkiye.
Objective: Opiorphin is a pentapeptide secreted in saliva and has a strong analgesic effect. Salivary opiorphin has been shown to increase in orofacial pain and may act as a pain reliever in pain caused by denture-related ulcers. The current study aimed to evaluate the salivary opiorphin levels in traumatic ulcers caused by ill-fitting dentures and demonstrate whether there is any correlation between trauma-related pain levels and salivary opiorphin levels.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!